CMMB insider filings
Chemomab Therapeutics Ltd. — 37 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-01. Screen CMMB transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 1 insider filing (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 1 filing by 1 insider — 2,304 shares, $6,516 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 7.
- Largest priced transaction: sale of 1,304 shares @ $2.85 ($3,716) by Cohen Neil Harris, filed 2026-09-01.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Cohen Neil Harris — Director | 1 | — | 2 legs · 2,304 sh · $6,516 | 7 |
Recent insider filings — Chemomab Therapeutics Ltd.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-01 | 4 | Cohen Neil Harris — Director | Sale (S): 1,304 @ $2.85 · Sale (S): 1,000 @ $2.80 · Grant/award (A): 172 (derivative) @ $0 · Grant/award (A): 2,971 (derivative) @ $0 · Grant/award (A): 1,705 (derivative) @ $0 · Grant/award (A): 1,714 (derivative) @ $0 · +3 more | EDGAR |
| 2026-06-01 | 4 | Mor George Adi — Chief Executive Officer, Director | Purchase (P): 4,878 @ $2.05 · Purchase (P): 4,926 @ $2.08 · Other (J): 31,712 · Other (J): 18,750 | EDGAR |
| 2023-07-05 | 4 | Darvish Nissim — Director | Grant/award (A): 20,572 (derivative) @ $0 · Grant/award (A): 6,857 (derivative) @ $0 · Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 · Grant/award (A): 10,123 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | Quigley Jill M. — Director | Grant/award (A): 6,857 (derivative) @ $0 · Grant/award (A): 13,640 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Fatal Sigal — Chief Financial Officer | Grant/award (A): 102,860 (derivative) @ $0 · Grant/award (A): 29,400 (derivative) @ $0 · Grant/award (A): 35,600 (derivative) @ $0 | EDGAR |
| 2023-03-23 | 4 | Moses Alan Charles — Director | Grant/award (A): 6,857 (derivative) @ $0 · Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 | EDGAR |
| 2023-03-23 | 4 | Nicaise Claude — Director | Grant/award (A): 6,857 (derivative) @ $0 · Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 | EDGAR |
| 2023-03-23 | 4 | Cohen Neil Harris — Director | Grant/award (A): 6,875 (derivative) @ $0 · Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 · Grant/award (A): 688 (derivative) @ $0 | EDGAR |
| 2023-03-23 | 4 | Darvish Nissim — Director | Grant/award (A): 6,857 (derivative) @ $0 · Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 · Grant/award (A): 10,123 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Mor George Adi — Chief Scientific Officer, Director | Sale (S): 7,700 @ $5.03 · Sale (S): 6,100 @ $5.03 · Grant/award (A): 131,698 (derivative) @ $0 · Grant/award (A): 33,725 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | OrbiMed Israel GP Ltd. — 10% owner OrbiMed Israel BioFund GP Limited Partnership — 10% owner | Sale (S): 266,376 @ $3.34 · Sale (S): 70,524 @ $4.51 | EDGAR |
| 2022-11-18 | 4 | Cohen Neil Harris — Director | Sale (S): 2,409 @ $2 · Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 · Grant/award (A): 688 (derivative) @ $0 | EDGAR |
| 2022-11-17 | 4 | Mor George Adi — Chief Scientific Officer, Director | Sale (S): 324,775 @ $2.08 · Sale (S): 257,248 @ $2.08 · Grant/award (A): 131,698 (derivative) @ $0 · Grant/award (A): 33,725 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | Marvin Donald — Executive VP, CFO & COO | Purchase (P): 250 @ $3.30 · Purchase (P): 250 @ $3.25 · Grant/award (A): 196,875 (derivative) @ $0 | EDGAR |
| 2022-05-25 | 4 | Maryles Joel Michael — Director | Purchase (P): 400 @ $2.89 · Purchase (P): 33 @ $2.76 · Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | Cohen Neil Harris — Director | Purchase (P): 2,000 @ $3.19 · Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 · Grant/award (A): 688 (derivative) @ $0 | EDGAR |
| 2022-03-21 | 4 | Maryles Joel Michael — Director | Purchase (P): 500 @ $4.32 · Purchase (P): 500 @ $4.36 · Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 | EDGAR |
| 2022-03-21 | 4 | Marvin Donald — Executive VP, CFO & COO | Purchase (P): 250 @ $4 · Purchase (P): 250 @ $3.98 · Purchase (P): 250 @ $3.90 · Purchase (P): 250 @ $4.10 · Purchase (P): 250 @ $4.20 · Grant/award (A): 196,875 (derivative) @ $0 | EDGAR |
| 2022-03-15 | 4 | Cohen Neil Harris — Director | Purchase (P): 2,000 @ $4.20 · Purchase (P): 2,000 @ $4.30 · Purchase (P): 2,000 @ $4.56 · Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 · Grant/award (A): 688 (derivative) @ $0 | EDGAR |
| 2022-03-15 | 4 | Pfost Dale R — Chief Executive Officer, Director | Purchase (P): 1,800 @ $3.98 · Purchase (P): 700 @ $3.97 · Grant/award (A): 459,353 (derivative) @ $0 | EDGAR |
| 2022-03-14 | 4 | Darvish Nissim — Director | Purchase (P): 1,200 @ $4.28 · Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 · Grant/award (A): 10,123 (derivative) @ $0 | EDGAR |
| 2022-03-09 | 4 | Darvish Nissim — Director | Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 | EDGAR |
| 2022-03-09 | 4 | Nicaise Claude — Director | Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 | EDGAR |
| 2022-03-09 | 4 | Cohen Neil Harris — Director | Grant/award (A): 6,820 (derivative) @ $0 | EDGAR |
| 2022-03-09 | 4 | Moses Alan Charles — Director | Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 | EDGAR |
| 2022-03-09 | 4 | Maryles Joel Michael — Director | Grant/award (A): 6,820 (derivative) @ $0 · Grant/award (A): 11,884 (derivative) @ $0 | EDGAR |
| 2021-12-08 | 4 | Cohen Neil Harris — Director | Purchase (P): 2,000 @ $7.43 | EDGAR |
| 2021-05-10 | 4 | Fatal Sigal — Chief Financial Officer | Grant/award (A): 35,653 (derivative) @ $0 | EDGAR |
| 2021-04-21 | 4 | Nicaise Claude — Director | Grant/award (A): 11,884 (derivative) @ $0 | EDGAR |
| 2021-04-21 | 4 | Moses Alan Charles — Director | Grant/award (A): 11,884 (derivative) @ $0 | EDGAR |
| 2021-04-21 | 4 | Maryles Joel Michael — Director | Grant/award (A): 11,884 (derivative) @ $0 | EDGAR |
| 2021-04-21 | 4 | Darvish Nissim — Director | Grant/award (A): 11,884 (derivative) @ $0 | EDGAR |
| 2021-04-21 | 4 | Cohen Neil Harris — Director | Grant/award (A): 11,884 (derivative) @ $0 | EDGAR |
| 2021-04-21 | 4 | SQUINTO STEPHEN P — Director | Grant/award (A): 23,768 (derivative) @ $0 | EDGAR |
| 2021-03-26 | 4 | Cohen Neil Harris — Director | Purchase (P): 2,409 @ $41.51 · Purchase (P): 688 (derivative) @ $0 | EDGAR |
| 2021-03-18 | 4 | OrbiMed Israel GP Ltd. — 10% owner OrbiMed Israel BioFund GP Limited Partnership — 10% owner | Grant/award (A): 288,170 @ $17.35 · Grant/award (A): 28,817 (derivative) | EDGAR |
| 2021-03-18 | 4 | THIEL PETER — 10% owner | Purchase (P): 230,536 · Purchase (P): 23,054 (derivative) | EDGAR |
Recent 8-K events — Chemomab Therapeutics Ltd.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-06-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-06-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-21 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-01-11 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-01-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-11-29 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-11-16 | 8-K | 8.01 — Other Events | EDGAR |
| 2022-11-14 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CMMB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs